key: cord-0946608-b5m802ww
authors: Legro, Richard S.
title: Coronavirus disease 2019 vaccination in women seeking pregnancy or in early pregnancy: What is there to debate?
date: 2021-06-18
journal: Fertil Steril
DOI: 10.1016/j.fertnstert.2021.05.084
sha: 44c94712592e8a4736b91bcfd06606c5aae44308
doc_id: 946608
cord_uid: b5m802ww

nan

Coronavirus disease 2019 vaccination in women seeking pregnancy or in early pregnancy: What is there to debate?

This issue's Fertile Battle debates what for several clinicians is a nonissue, that is, coronavirus disease 2019 (COVID-19) vaccination in women seeking pregnancy or in early pregnancy. The overwhelming consensus supported by the recommendations from the Centers for Disease Control and Prevention and our governing professional societies is that it should be offered to most patients in these categories. Such recommendations, if incorporated into guidelines, may have a mixed risk-benefit ratio, especially if they are based on limited or misinterpreted clinical trial information (1). Moreover, once promulgated, they are difficult, in the absence of data, to modify. Questioning the maternal COVID-19 vaccination recommendations, given the well-documented risks to women who are pregnant by COVID-19 infection, can be considered a threat to women's health and perhaps also a threat to science given the extensive research that has been carried out into the development and testing of these vaccines.

Let me reassure the readership that there are no antivaxxers or doubters of science among the authors of this debate. The authors of both the pro and con sections (confession: I am one of the authors of the con section) of this Fertile Battle are strong proponents of vaccination but, in the spirit of debate, have focused their arguments on their assigned sides. This battle was designed to link up an expert in reproductive endocrinology (myself at Penn State and Dr. Meredith Snook at the University of Pittsburgh) with an expert in viral illnesses and vaccination (Dr. Catharine Paules, an infectious diseases specialist [Internal Medicine background] at Penn State, and Dr. Richard Beigi, an infectious disease specialist [Obstetrics and Gynecology background] at the University of Pittsburgh). Since these latter authors may be less known to the readers of the journal and members of the Society, I would like to take some space to highlight their research and expertise in the field of viral diseases and vaccination.

Dr. Paules came to Penn State Health from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health where her expertise was in emerging infectious diseases, particularly influenza and related countermeasure development. She has participated as the site Principal Investigator at Penn State Health for the National Institute of Allergy and Infectious Diseases-sponsored Adaptive COVID-19 Treatment trial and authored a highly cited perspective piece on COVID-19 (2, 3) . Her work published before the current pandemic is prescient of the challenges emerging infectious diseases present as well as the role of research in countering them. This experience aided her and myself in the development of a con section highlighting the importance of clinical trial data in forming medical recommendations.

Dr. Richard Beigi is one of the world's leading authorities on viral illnesses and vaccinations during pregnancy (in addition to his ''day job'' as President of Magee-Womens Hospital with the largest obstetric volume of any hospital in Pennsylvania). He has studied the effects of viral illnesses on pregnancy, antiviral treatments during pregnancy, and multiple types of vaccinations for various infectious illnesses during pregnancy; examined barriers to maternal vaccination; and participated in multiple expert panels of vaccination and pregnancy (4) . He has been a strong advocate for the inclusion of women who are pregnant in vaccination trials, including COVID-19 vaccination trials (5) . He and Dr. Snook have collated the evidence and rationale for immediate vaccination in our target population in the pro side of the debate.

I am certain that this well-qualified group of authors could easily take the opposite position and defend it cogently. The purpose of this article is to highlight the current state of knowledge of the risks of COVID-19 infection during pregnancy and risks and benefits of vaccination in the populations of women that providers of infertility care most commonly see to allow for informed decision-making. Hopefully, it will also cause a questioning of the status quo for the drug and vaccine development for women who are pregnant and prepare us to better anticipate the issues of vaccination that will arise in this population during the next pandemic.

Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines

Baricitinib plus remdesivir for hospitalized adults with Covid-19

Coronavirus infections-more than just the common cold

Research on vaccines during pregnancy: protocol design and assessment of safety

The need for inclusion of pregnant women in COVID-19 vaccine trials